Table E1.
Characteristics from 33 individuals fully vaccinated with ChAdOx1
| Patient ID | Age (years) | Sex | Days after second dose | NT analysis | Total anti-RBD Ig (Wantai) |
Anti-S1 IgG (Euroimmun) |
Anti-S1 IgA (Euroimmun) |
|||
|---|---|---|---|---|---|---|---|---|---|---|
| Results | RoA | Results | Concentration (BAU∙mL−1) | Results | RoA | |||||
| A1 | 25 | F | 29 | Yes | Positive | 17.64 | Positive | 337.88 | Positive | 0.82 |
| A2 | 26 | M | 29 | Yes | Positive | 17.89 | Positive | 127.84 | Negative | 0.55 |
| A3 | 28 | M | 29 | Yes | Positive | 17.82 | Positive | 203.20 | Positive | 1.43 |
| A4 | 28 | M | 29 | Yes | Positive | 17.58 | Positive | 264.62 | Negative | 0.49 |
| A5 | 28 | F | 29 | Yes | Positive | 17.86 | Positive | 264.39 | Negative | 0.50 |
| A6 | 29 | M | 29 | Yes | Positive | 18.15 | Positive | 162.23 | Negative | 0.49 |
| A7 | 30 | F | 29 | Yes | Positive | 17.91 | Negative | 22.90 | Negative | 0.28 |
| A8 | 35 | M | 29 | Yes | Positive | 18.96 | Positive | 181.26 | Negative | 0.61 |
| A9 | 38 | F | 29 | Yes | Positive | 17.66 | Positive | 189.57 | Positive | 2.03 |
| A10 | 39 | M | 29 | Yes | Positive | 17.90 | Positive | 227.50 | Positive | 0.89 |
| A11 | 39 | M | 29 | Yes | Positive | 18.36 | Positive | 191.57 | Positive | 1.46 |
| A12 | 41 | F | 29 | Yes | Positive | 18.35 | Positive | 173.14 | Negative | 0.37 |
| A13 | 42 | M | 29 | Yes | Positive | 18.73 | Positive | 164.09 | Positive | 1.34 |
| A14 | 42 | M | 29 | Yes | Positive | 19.13 | Positive | 152.04 | Positive | 1.55 |
| A15 | 45 | F | 29 | Yes | Positive | 20.24 | Positive | 373.22 | Positive | 1.69 |
| A16 | 47 | M | 29 | Yes | Positive | 19.28 | Positive | 125.39 | Negative | 0.36 |
| A17 | 47 | F | 29 | Yes | Positive | 17.85 | Positive | 168.21 | Negative | 0.60 |
| A18 | 47 | F | 29 | Yes | Positive | 18.67 | Positive | 453.82 | Positive | 1.18 |
| A19 | 50 | F | 29 | Yes | Positive | 18.18 | Positive | 375.76 | Negative | 0.55 |
| A20 | 56 | F | 29 | Yes | Positive | 18.45 | Positive | 267.71 | Positive | 4.44 |
| A21 | 57 | F | 29 | Yes | Positive | 19.20 | Positive | 318.41 | Positive | 1.36 |
| A22 | 58 | F | 29 | Yes | Positive | 18.64 | Positive | 197.86 | Negative | 0.51 |
| A23 | 58 | F | 36 | Yes | Positive | 17.55 | Positive | 149.36 | Negative | 0.26 |
| A24 | 61 | M | 36 | Yes | Positive | 17.92 | Positive | 358.77 | Negative | 0.63 |
| A25 | 62 | F | 29 | Yes | Positive | 18.86 | Positive | 108.98 | NA | NA |
| A26 | 51 | M | 29 | No | Positive | 18.58 | Positive | 540.93 | Positive | 6.11 |
| A27 | 42 | M | 29 | No | Positive | 18.81 | Positive | 259.92 | Positive | 1.16 |
| A28 | 56 | M | 29 | No | Positive | 18.07 | Positive | 429.08 | Positive | 0.82 |
| A29 | 32 | F | 29 | No | Positive | 18.36 | Positive | 534.19 | Positive | 2.36 |
| A30 | 47 | F | 29 | No | Positive | 17.86 | Positive | 423.68 | Negative | 0.67 |
| A31 | 51 | F | 34 | No | Positive | 19.79 | Positive | 259.45 | Negative | 0.51 |
| A32 | 39 | F | 33 | No | Positive | 19.21 | Positive | 462.21 | Positive | 2.36 |
| A33 | 51 | F | 33 | No | Positive | 18.27 | Positive | 350.28 | Negative | 0.61 |
Results for total Ig against SARS-CoV-2 RBD and for IgA against SARS-CoV-2 domain S1 are shown as RoA. For IgG against SARS-CoV-2 domain, S1 results are presented in binding antibody units per milliliter of serum (BAU∙mL−1). Serum samples used for the neutralization experiments are indicated in “NT analysis” column. The average age of the participants was 43 years; the percentage of women was 58%. All samples from ChAdOx1 vaccinees were taken between 29 and 36 days after receipt of the second dose. NA, Not applicable.